Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma

被引:3
作者
Chang, Hsin-Yi [1 ,2 ]
Dermawan, Josephine K. [3 ]
Kuba, Maria Gabriela [2 ]
Crago, Aimee M. [4 ,5 ]
Singer, Samuel [4 ]
Tap, William [6 ,7 ]
Chi, Ping [6 ,7 ]
D'Angelo, Sandra [6 ,7 ]
Rosenbaum, Evan [6 ,7 ]
Antonescu, Cristina R. [2 ,8 ]
机构
[1] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA
[3] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland Hts, OH USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Gastr Mixed Tumor Serv, New York, NY USA
[5] Weill Cornell Med Ctr, Dept Surg, New York, NY USA
[6] Mem Sloan Kettering Canc Ctr, Dept Med, Sarcoma Serv, New York, NY USA
[7] Weill Cornell Med Ctr, Dept Med, New York, NY USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
angiosarcoma; breast; genomic landscape; neoadjuvant chemotherapy; pathologic response; radiation-associated; ATYPICAL VASCULAR-LESIONS; RADIATION-INDUCED ANGIOSARCOMA; GENE AMPLIFICATION; MYC AMPLIFICATION; GEMCITABINE; HYBRIDIZATION; DOCETAXEL; SARCOMAS; OUTCOMES; CANCER;
D O I
10.1002/gcc.23240
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both primary and secondary breast angiosarcoma (AS) are characterized by multifocal presentation and aggressive behavior. Despite multimodality therapy, local and distant relapse rates remain high. Therefore, neoadjuvant chemotherapy (NACT) is employed to improve the R0 resection rates and survival, but its benefits remain controversial. Herein, we investigate pathologic and molecular correlates to NACT-induced histologic response in a group of 29 breast AS, 4 primary and 25 radiation-associated (RA). The two NACT regimens applied were anthracycline- and non-anthracycline-based. The pathologic response grade was defined as: I: <= 50%, II: 51%-90%, III: 91%-99%, and IV: 100%. An additional 45 primary AS and 102 RA-AS treated by surgery alone were included for survival comparison. The genomic landscape was analyzed in a subset of cases and compared to a cohort of AS without NACT on a paired tumor-normal targeted DNA NGS platform. All patients were females, with a median age of 31 years in primary AS and 68 years in RA-AS. All surgical margins were negative in NACT group. The NACT response was evenly divided between poor (Grades I-II; n = 15) and good responders (Grades III-IV; n = 14). Mitotic count >10/mm2 was the only factor inversely associated with pathologic response. By targeted NGS, all 10 post-NACT RA-AS demonstrated MYC amplification, while both primary AS harbored KDR mutations. TMB or other genomic alterations did not correlate with pathologic response. All four patients with Grade IV response remained free of disease. The good responders had a significantly better disease-specific survival (p = 0.04). There was no survival difference with NACT status or the NACT regimens applied. However, NACT patients with MYC-amplified tumors showed better disease-free survival (p = 0.04) compared to MYC-amplified patients without NACT. The overall survival of NACT group correlated with size >10 cm (p = 0.02), pathologic response (p = 0.04), and multifocality (p = 0.01) by univariate, while only size >10 cm (p = 0.03) remained significant by multivariate analysis.
引用
收藏
页数:12
相关论文
共 35 条
[1]   Treatment and outcome of 82 patients with angiosarcoma [J].
Abraham, John A. ;
Hornicek, Francis J. ;
Kaufman, Adam M. ;
Harmon, David C. ;
Springfield, Dempsey S. ;
Raskin, Kevin A. ;
Mankin, Henry J. ;
Kirsch, David G. ;
Rosenberg, Andrew E. ;
Nielsen, G. Petur ;
Desphpande, Vikram ;
Suit, Herman D. ;
DeLancy, Thomas F. ;
Yoon, Sam S. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (06) :1953-1967
[2]   Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma [J].
Abu Saleh, Walid K. ;
Ramlawi, Basel ;
Shapira, Oz M. ;
Al Jabbari, Odeaa ;
Ravi, Vinod ;
Benjamin, Robert ;
Durand, Jean-Bernard ;
Leja, Monika J. ;
Blackmon, Shanda H. ;
Bruckner, Brian A. ;
Reardon, Michael J. .
ANNALS OF THORACIC SURGERY, 2017, 104 (01) :90-97
[3]   Thalidomide Combined with Neoadjuvant Chemotherapy in Angiosarcoma of the Breast with Complete Pathologic Response: Case Report and Review of Literature [J].
Alvarado-Miranda, Alberto ;
Bacon-Fonseca, Ludwing ;
Lara-Medina Fernando, Ulises ;
Maldonado-Martinez, Hector ;
Arce-Salinas, Claudia .
BREAST CARE, 2013, 8 (01) :74-76
[4]   KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors [J].
Antonescu, Cristina R. ;
Yoshida, Akihiko ;
Guo, Tianhuo ;
Chang, Ning-En ;
Zhang, Lei ;
Agaram, Narasimhan P. ;
Qin, Li-Xuan ;
Brennan, Murray F. ;
Singer, Samuel ;
Maki, Robert G. .
CANCER RESEARCH, 2009, 69 (18) :7175-7179
[5]   Neoadjuvant Gemcitabine-Taxane Chemotherapy for Radiation-Induced Angiosarcoma of the Breast: A Case Report [J].
Arnaout, Angel ;
Wedman, Dawn M. ;
El-Sayed, Samy ;
Acharya, Virbala ;
Lad, Shilpa .
BREAST JOURNAL, 2012, 18 (03) :276-278
[6]   ANGIOSARCOMA OF THE BREAST AND PREGNANCY - A NEW THERAPEUTIC APPROACH [J].
BARRENETXEA, G ;
SCHNEIDER, J ;
TANAGO, JG ;
PEREZ, C ;
CENTENO, MM ;
RODRIGUEZESCUDERO, FJ .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1995, 60 (01) :87-89
[7]   Recurrent PTPRB and PLCG1 mutations in angiosarcoma [J].
Behjati, Sam ;
Tarpey, Patrick S. ;
Sheldon, Helen ;
Martincorena, Inigo ;
Van Loo, Peter ;
Gundem, Gunes ;
Wedge, David C. ;
Ramakrishna, Manasa ;
Cooke, Susanna L. ;
Pillay, Nischalan ;
Vollan, Hans Kristian M. ;
Papaemmanuil, Elli ;
Koss, Hans ;
Bunney, Tom D. ;
Hardy, Claire ;
Joseph, Olivia R. ;
Martin, Sancha ;
Mudie, Laura ;
Butler, Adam ;
Teague, Jon W. ;
Patil, Meena ;
Steers, Graham ;
Cao, Yu ;
Gumbs, Curtis ;
Ingram, Davis ;
Lazar, Alexander J. ;
Little, Latasha ;
Mahadeshwar, Harshad ;
Protopopov, Alexei ;
Al Sannaa, Ghadah A. ;
Seth, Sahil ;
Song, Xingzhi ;
Tang, Jiabin ;
Zhang, Jianhua ;
Ravi, Vinod ;
Torres, Keila E. ;
Khatri, Bhavisha ;
Halai, Dina ;
Roxanis, Ioannis ;
Baumhoer, Daniel ;
Tirabosco, Roberto ;
Amary, M. Fernanda ;
Boshoff, Chris ;
McDermott, Ultan ;
Katan, Matilda ;
Stratton, Michael R. ;
Futreal, P. Andrew ;
Flanagan, Adrienne M. ;
Harris, Adrian ;
Campbell, Peter J. .
NATURE GENETICS, 2014, 46 (04) :376-+
[8]  
Brenn T, 2005, AM J SURG PATHOL, V29, P983
[9]   Angiosarcoma Outcomes and Prognostic Factors A 25-Year Single Institution Experience [J].
Buehler, Darya ;
Rice, Stephanie R. ;
Moody, John S. ;
Rush, Patrick ;
Hafez, Gholam-Reza ;
Attia, Steven ;
Longley, B. Jack ;
Kozak, Kevin R. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (05) :473-479
[10]   Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology [J].
Cheng, Donavan T. ;
Mitchell, Talia N. ;
Zehir, Ahmet ;
Shah, Ronak H. ;
Benayed, Ryma ;
Syed, Aijazuddin ;
Chandramohan, Raghu ;
Liu, Zhen Yu ;
Won, Helen H. ;
Scott, Sasinya N. ;
Brannon, A. Rose ;
O'Reilly, Catherine ;
Sadowska, Justyna ;
Casanova, Jacklyn ;
Yannes, Angela ;
Hechtman, Jaclyn F. ;
Yao, Jinjuan ;
Song, Wei ;
Ross, Dara S. ;
Oultache, Alifya ;
Dogan, Snjezana ;
Borsu, Laetitia ;
Hameed, Meera ;
Nafa, Khedoudja ;
Arcila, Maria E. ;
Ladanyi, Marc ;
Berger, Michael F. .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03) :251-264